Gene expression‐based chemical genomics identifies heat‐shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma

Cholangiocarcinoma (CCA) is an aggressive tumor with a poor prognosis. There is no standard therapy for CCA, and novel drugs for treating refractory CCA need to be identified.

[1]  W. Weng,et al.  Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA. , 2011, World journal of gastroenterology.

[2]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[3]  A. Jimeno,et al.  KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Hergenrother,et al.  Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. , 2011, ACS chemical biology.

[5]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[6]  T. Yen,et al.  Animal PET for Thioacetamide-Induced Rat Cholangiocarcinoma: A Novel and Reliable Platform , 2008, Molecular Imaging and Biology.

[7]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[8]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[9]  C. Scheidereit,et al.  Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. , 2004, Oncogene.

[10]  Cheng-Yan Kao,et al.  Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma , 2011, PloS one.

[11]  Ju-Hee Lee,et al.  Antitumor activity of NVP‐AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins , 2011, Cancer science.

[12]  J. Sloan,et al.  Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[14]  M. Nagino,et al.  Hepatectomy With Simultaneous Resection of the Portal Vein and Hepatic Artery for Advanced Perihilar Cholangiocarcinoma: An Audit of 50 Consecutive Cases , 2010, Annals of surgery.

[15]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[16]  S. Friend,et al.  Accelerating drug discovery: Open source cancer cell biology? , 2006, Cancer cell.

[17]  C. Hudis,et al.  Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[19]  A. Zhu,et al.  Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities , 2011, Hepatology.

[20]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[21]  E. Gaudio,et al.  Cholangiocarcinoma: update and future perspectives. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[22]  Andrea Frilling,et al.  Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. , 2008, World journal of gastroenterology.

[23]  Yusuke Nakamura,et al.  Comparison of gene expression profiles between Opisthorchis viverrini and non‐Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma , 2006, Hepatology.

[24]  Paul Workman,et al.  Drugging the Cancer Chaperone HSP90 , 2007, Annals of the New York Academy of Sciences.

[25]  Y. Bayraktar,et al.  Cholangiocarcinoma: a compact review of the literature. , 2008, World journal of gastroenterology.

[26]  Y. Jan,et al.  Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. , 2003, Carcinogenesis.

[27]  A. Rowan.  Guide for the Care and Use of Laboratory Animals , 1979 .

[28]  A. Zhu,et al.  Genetics of biliary tract cancers and emerging targeted therapies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Vassal,et al.  Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma , 2010, Molecular Cancer Therapeutics.

[30]  C. McNeil.  Herceptin raises its sights beyond advanced breast cancer. , 1998, Journal of the National Cancer Institute.

[31]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.